Oncotarget is Instrumental in Helping to Make Strides Against Thyroid Cancer

spcblog, 26 December 2017, No comments
Categories: Health

There is a medical and oncology journal that surfaced some years ago called Oncotarget. What makes it special is that Oncotarget is almost entirely devoted to treatment of cancer and cancer research, with a few other medical subjects introduced from time to time.

Oncotarget is the brain child of the two editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov (Roswell Park Cancer Institute). They started the semiweekly digest in 2010, and the journal has gained acceptance and use throughout the world. It is currently within the top four journals used as a resource by cancer researchers and other doctors. Visit Soundcloud to listen an audio podcast of Oncotarget.

Mikhail Blagosklonny earned his MD in medicine from the University of St. Petersburg. Later, he returned and earned a doctorate in medical research from the same university.

Follow: https://twitter.com/oncotargetjrnl?lang=en

What makes Oncotarget unique is that it is published semiweekly (twice per week), and is made instantly and readily available throughout the world to any medical professional or researcher. Oncotarget has bee of invaluable aid in other forms of research as well, though its main focus is of course, oncology — the study of cancer and its treatments.

As recently as July of 2017, Oncotarget published articles on new treatments for thyroid cancer. A new inhibitor for thyroid cancer had been developed and described in the journal, and doctors were able to observe the results of the study on the patients involved. This was something of a breakthrough for the oncology field. Oncotarget had a profound impact on the ability of researchers to share their information with doctors treating thyroid cancer. This immediate online use of a medical journal to diagnose and treat cancer was something new for most of the researchers and doctors, as well as the patients involved. Listen to Oncotarget podcast on Player.FM.


Leave a Reply:

Name *

Mail (hidden) *